<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04065399</url>
  </required_header>
  <id_info>
    <org_study_id>SNDX-5613-0700</org_study_id>
    <nct_id>NCT04065399</nct_id>
  </id_info>
  <brief_title>A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation</brief_title>
  <acronym>AUGMENT-101</acronym>
  <official_title>AUGMENT-101: A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX 5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syndax Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Syndax Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase&#xD;
      2 dose (RP2D) of SNDX-5613 in patients with acute leukemia.&#xD;
&#xD;
      In Phase 2, patients will be enrolled in 3 indication-specific expansion cohorts to determine&#xD;
      the efficacy, short- and long-term safety, and tolerability of SNDX-5613.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1 dose escalation will determine the maximum tolerated dose (MTD), and recommended&#xD;
      Phase 2 dose (RP2D) of SNDX-5613 in patients with acute leukemia harboring an MLL&#xD;
      rearrangement or NPM1 mutation:&#xD;
&#xD;
        -  Arm A: Patients not receiving any strong cytochrome P450 3A4 (CYP3A4) inhibitor/&#xD;
           inducers.&#xD;
&#xD;
        -  Arm B: Patients receiving strong cytochrome P450 3A4 (CY3A4) inhibitors for antifungal&#xD;
           prophylaxis.&#xD;
&#xD;
        -  Arm C: Patients receiving SNDX-5613 in combination with cobicistat.&#xD;
&#xD;
      In Phase 2, patients will be enrolled in 3 indication-specific expansion cohorts to determine&#xD;
      the efficacy, short- and long-term safety, and tolerability of SNDX-5613:&#xD;
&#xD;
        -  Cohort 2A: Patients with MLLr acute lymphoblastic leukemia (ALL)/mixed phenotype acute&#xD;
           leukemia (MPAL).&#xD;
&#xD;
        -  Cohort 2B: Patients with MLLr AML.&#xD;
&#xD;
        -  Cohort 2C: Patients with NPM1c AML.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Phase 1 will employ an accelerated titration design. The dose escalation will follow a modified Fibonacci sequence.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of dose-limiting toxicities (DLTs) (Phase 1)</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Assessed by the NCI CTCAE version 5.0 (Phase 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency, duration, and severity of treatment-emergent adverse events (TEAEs) (Phase 1)</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Assessed by the NCI CTCAE version 5.0 (Phase 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency, duration, and severity of treatment-related TEAEs (TRAEs) (Phase 1)</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Assessed by the NCI CTCAE version 5.0 (Phase 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency, duration, and severity of serious adverse events (SAEs) (Phase 1)</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Assessed by the NCI CTCAE version 5.0 (Phase 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (Phase 1)</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Maximum plasma concentration (CMAX) of SNDX-5613 (Phase 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax (Phase 1)</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Time to observed maximum plasma concentration of SNDX-5613 (Phase 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t (Phase 1)</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to time of last measurable concentration of SNDX-5613 (Phase 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24 (Phase 1)</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to 24 hours (Phase 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F (Phase 1)</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Apparent oral clearance of SNDX-5613 (Phase 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F (Phase 1)</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Apparent volume of distribution of SNDX-5613 (Phase 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 (Phase 1)</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Terminal phase half-life of SNDX-5613 (Phase 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete remission (CR) rate (Phase 2)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>To assess the CR rate (CR+CRh). (Phase 2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of adverse events (AEs) (Phase 2)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Assessed by the NCI CTCAE version 5.0 (Phase 2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of serious adverse events (SAEs) (Phase 2)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Assessed by the NCI CTCAE version 5.0 (Phase 2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency, duration, and severity of treatment-emergent adverse events (TEAEs) (Phase 2)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Assessed by the NCI CTCAE version 5.0 (Phase 2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency, duration, and severity of treatment-related TEAEs (TRAEs) (Phase 2)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Assessed by the NCI CTCAE version 5.0 (Phase 2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite definition of complete remission (CRc) Rate (Phase 2)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>To assess the CRc rate. (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission with partial hematologic recovery (CR+CRh) rate after 4 weeks of therapy (Phase 2)</measure>
    <time_frame>Approximately 19 months</time_frame>
    <description>To assess the CR (CR+CRh) rate after 4 weeks of therapy. (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BORR (CRc+ partial remission [PR]). (Phase 2)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>To assess the best overall remission rate (BORR) of SNDX-5613 (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median RFS (Phase 2)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>To assess relapse-free survival of SNDX-5613 (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTR (Phase 2)</measure>
    <time_frame>Approximately 34 months</time_frame>
    <description>To assess the time to response (TTR) of SNDX-5613 (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR (Phase 2)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>To assess the duration of response (DOR) of SNDX-5613 (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS (Phase 2)</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>To assess overall survival of SNDX-5613 (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (Phase 2)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Maximum plasma concentration (CMAX) of SNDX-5613 (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax (Phase 2)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Time to observed maximum plasma concentration of SNDX-5613 (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t (Phase 2)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to time of last measurable concentration of SNDX-5613 (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24 (Phase 2)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to 24 hours (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (Phase 2)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Apparent oral clearance of SNDX-5613 (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F (Phase 2)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Apparent volume of distribution of SNDX-5613 (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 (Phase 2)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Terminal phase half-life of SNDX-5613 (Phase 2)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Mixed Lineage Acute Leukemia</condition>
  <condition>Mixed Phenotype Acute Leukemia</condition>
  <condition>Acute Leukemia of Ambiguous Lineage</condition>
  <arm_group>
    <arm_group_label>Experimental: SNDX-5613</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1:&#xD;
Oral SNDX-5613; sequential cohorts of escalating dose levels of SNDX-5613 to identify the maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D). Patients will be enrolled in one of three dose-escalation arms:&#xD;
Arm A: Patients not receiving any strong cytochrome P450 3A4 (CYP3A4) inhibitor/ inducers.&#xD;
Arm B: Patients receiving strong cytochrome P450 3A4 inhibitors for antifungal prophylaxis.&#xD;
Arm C: Patients receiving SNDX-5613 and cobicistat.&#xD;
Phase 2:&#xD;
Oral SNDX-5613; Following the determination of the RP2D in Phase 1, 3 indication-specific expansion cohorts will be enrolled as follows:&#xD;
Cohort 2A: Patients with MLLr acute lymphoblastic leukemia (ALL)/mixed phenotype acute leukemia (MPAL).&#xD;
Cohort 2B: Patients with MLLr AML.&#xD;
Cohort 2C: Patients with NPM1c AML.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SNDX-5613</intervention_name>
    <description>SNDX-5613 orally</description>
    <arm_group_label>Experimental: SNDX-5613</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cobicistat</intervention_name>
    <description>Phase 1 Arm C patients will receive 150 mg cobicistat daily.</description>
    <arm_group_label>Experimental: SNDX-5613</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients must have active acute leukemia (bone marrow blasts ≥ 5% or reappearance of blasts&#xD;
        in peripheral blood) as defined by the National Comprehensive Cancer Network (NCCN) in the&#xD;
        NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic&#xD;
        Leukemia (Version 1.2020) and Acute Myeloid Leukemia (Version 3.2020).&#xD;
&#xD;
          1. Phase 1: Documented R/R acute leukemia harboring MLL rearrangement or NPM1c mutation.&#xD;
&#xD;
               -  Arm A: Patients not receiving any strong cytochrome P450 3A4 (CYP3A4)&#xD;
                  inhibitor/inducers.&#xD;
&#xD;
               -  Arm B: Patients receiving strong cytochrome P450 3A4 inhibitors for antifungal&#xD;
                  prophylaxis.&#xD;
&#xD;
               -  Arm C: Patients receiving SNDX-5613 in combination with cobicistat.&#xD;
&#xD;
          2. Phase 2:&#xD;
&#xD;
               -  Cohort 2A: Documented R/R ALL/MPAL with an MLLr translocation.&#xD;
&#xD;
               -  Cohort 2B: Documented R/R AML with an MLLr translocation.&#xD;
&#xD;
               -  Cohort 2C: Documented R/R AML with NPM1c.&#xD;
&#xD;
          3. WBC must be below 50,000/ μL at time of enrollment. Patients may receive cytoreduction&#xD;
             prior to enrollment.&#xD;
&#xD;
          4. Male or female patient aged ≥30 days old.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status score 0-2 or&#xD;
             Karnofsky/Lansky score ≥40.&#xD;
&#xD;
          6. Any prior treatment-related toxicities resolved to ≤Grade 1 prior to enrollment, with&#xD;
             the exception of ≤Grade 2 neuropathy or alopecia.&#xD;
&#xD;
          7. Radiation Therapy: At least 60 days from prior total body irradiation (TBI),&#xD;
             craniospinal radiation and/or ≥50% radiation of the pelvis, or at least 14 days from&#xD;
             local palliative radiation therapy (small port).&#xD;
&#xD;
          8. Stem Cell Infusion: At least 60 days must have elapsed from HSCT and at least 4 weeks&#xD;
             (from first dose) must have elapsed from donor lymphocyte infusion (DLI) without&#xD;
             conditioning.&#xD;
&#xD;
          9. Immunotherapy: At least 42 days since prior immunotherapy, including tumor vaccines&#xD;
             and checkpoint inhibitors, and at least 21 days since receipt of chimeric antigen&#xD;
             receptor therapy or other modified T cell therapy.&#xD;
&#xD;
         10. Myelosuppressive Chemotherapy: At least 14 days since the completion of&#xD;
             cytotoxic/myelosuppressive therapy.&#xD;
&#xD;
         11. Hematopoietic Growth Factors: At least 7 days since the completion of therapy with&#xD;
             short-acting hematopoietic growth factors and 14 days with long-acting growth factors.&#xD;
&#xD;
         12. Biologics: At least 7 days or 5 half-lives, whichever is longer, since the completion&#xD;
             of therapy with a biologic agent.&#xD;
&#xD;
         13. Steroids: At least 7 days since systemic glucocorticoid therapy, unless receiving&#xD;
             physiologic dosing (equivalent to ≤10 mg prednisone daily) or cytoreductive therapy.&#xD;
&#xD;
         14. Adequate organ function.&#xD;
&#xD;
         15. If of childbearing potential, willing to use a highly effective method of&#xD;
             contraception or double barrier method from the time of enrollment through 120 days&#xD;
             following the last study drug dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients meeting any of the following criteria are not eligible for study participation:&#xD;
&#xD;
          1. Active diagnosis of acute promyelocytic leukemia.&#xD;
&#xD;
          2. Isolated extramedullary relapse.&#xD;
&#xD;
          3. Known CNS involvement (cytologic or radiographic).&#xD;
&#xD;
          4. Detectable human immunodeficiency virus (HIV) viral load within the previous 6 months.&#xD;
             Patients with a known history of HIV 1/2 antibodies must have viral load testing prior&#xD;
             to study enrollment.&#xD;
&#xD;
          5. Hepatitis B or C.&#xD;
&#xD;
          6. Pregnant or nursing women.&#xD;
&#xD;
          7. Cardiac Disease:&#xD;
&#xD;
             Any of the following within the 6 months prior to study entry: myocardial infarction,&#xD;
             uncontrolled/unstable angina, congestive heart failure (New York Heart Association&#xD;
             Classification Class ≥II), life-threatening, uncontrolled arrhythmia, cerebrovascular&#xD;
             accident, or transient ischemic attack.&#xD;
&#xD;
             - QTc &gt;450 msec for males and QTc &gt;450 msec for females.&#xD;
&#xD;
          8. Gastrointestinal Disease:&#xD;
&#xD;
               -  Chronic diarrhea or other gastrointestinal issue that might affect oral drug&#xD;
                  absorption or ingestion (ie, short-gut syndrome, gastroparesis, etc).&#xD;
&#xD;
               -  Cirrhosis with a Child-Pugh score of B or C.&#xD;
&#xD;
          9. Graft-Versus-Host Disease (GVHD): Signs or symptoms of acute or chronic GVHD &gt;Grade 0&#xD;
             within 4 weeks of enrollment. All transplant patients must have been off all systemic&#xD;
             immunosuppressive therapy and calcineurin inhibitors for at least 4 weeks prior to&#xD;
             enrollment. Patients may be on physiological doses of steroids.&#xD;
&#xD;
         10. Concurrent malignancy in the previous 2 years with the exception of basal cell&#xD;
             carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg,&#xD;
             breast carcinoma, cervical cancer in situ, melanoma in situ) treated with potentially&#xD;
             curative therapy. Concurrent malignancy must be in complete remission or no evidence&#xD;
             of disease during this timeframe.&#xD;
&#xD;
         11. Participation in another therapeutic interventional clinical study within 30 days of&#xD;
             enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Galit Rosen, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Syndax Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sue Fischer</last_name>
    <phone>781-795-9419</phone>
    <email>sfischer@syndax.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rick Cordova</last_name>
      <phone>626-218-3192</phone>
      <email>rcordova@coh.org</email>
    </contact>
    <contact_backup>
      <last_name>Emily Riffle</last_name>
      <phone>626-218-2312</phone>
      <email>eriffle@coh.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists and Research Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kris Howard, RN,OCN</last_name>
      <phone>941-377-9993</phone>
      <phone_ext>7255</phone_ext>
      <email>khoward@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Gleason, MLS, CCRC</last_name>
      <phone>404-778-4334</phone>
      <phone_ext>10808</phone_ext>
      <email>shannon.gleason@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howie Weiner, CCRP</last_name>
      <phone>773-702-2084</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morgan Johnson</last_name>
      <phone>857-215-0238</phone>
      <email>Morgan_Johnson@DFCI.HARVARD.EDU</email>
    </contact>
    <contact_backup>
      <last_name>Lindsay Rae</last_name>
      <phone>617-582-9169</phone>
      <email>Lindsey_Rae@DFCI.HARVARD.EDU</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Hartman</last_name>
      <phone>314-273-8628</phone>
      <email>hannahlhartman@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kait Tkachuk</last_name>
      <phone>646-608-2783</phone>
      <email>tkachukk@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prafulla Bhagat</last_name>
      <email>prafulla.bhagat@einsteinmed.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghayas Issa, MD</last_name>
      <email>gcissa@mdanderson.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 16, 2019</study_first_submitted>
  <study_first_submitted_qc>August 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2019</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>ALL</keyword>
  <keyword>acute leukemia</keyword>
  <keyword>MLLr</keyword>
  <keyword>KMT2A</keyword>
  <keyword>NPM1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Biphenotypic, Acute</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cobicistat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

